论文部分内容阅读
支气管哮喘是由Th2介导的Ⅰ型变态反应,与内源性IL-12生成不足有关,该文综述了IL-12的生物学效应、IL-12表达障碍与支气管哮喘的关系以及IL-12、重组IL-12(rIL-12)在支气管哮喘治疗方面的应用前景。IL-12与Ⅰ型变态反应关系密切,内源性IL-12表达不足使支气管哮喘患者免疫系统向Th2方向偏移,在过敏原或病毒等外因的刺激下发生支气管哮喘。用IL-12对支气管哮喘进行免疫治疗已在动物实验中取得了显著效果,将IL-12、rIL-12或IL-12的内源性诱生物应用于人体的方法也在不断探索中并取得了一定效果,基于IL-12的治疗方法可能为支气管哮喘等变应性疾病的免疫治疗开辟新的途径。
Bronchial asthma is a Th2-mediated type I allergic reaction that is associated with underproduction of endogenous IL-12. This article reviews the biological effects of IL-12, the relationship between IL-12 expression and bronchial asthma, and the role of IL-12 , And the prospect of recombinant IL-12 (rIL-12) in the treatment of bronchial asthma. IL-12 is closely related to type I allergic reaction. The lack of endogenous IL-12 expression shifts the immune system of asthma patients toward Th2, and bronchial asthma occurs when stimulated by external factors such as allergens or viruses. Immunotherapy of bronchial asthma with IL-12 has achieved remarkable results in animal experiments. Methods of applying endogenous inducements of IL-12, rIL-12 or IL-12 to the human body are also being explored and obtained A certain effect, IL-12-based treatment may open up new avenues for immunotherapy of allergic diseases such as bronchial asthma.